Skip to main content
Clinical Trials/JPRN-jRCTs032200430
JPRN-jRCTs032200430
Recruiting
Phase 3

Cochlear implantation for unilateral severe to profound hearing loss

Iwasaki Satoshi0 sites38 target enrollmentApril 1, 2021

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
nilateral severe to profound sensorineural hearing loss
Sponsor
Iwasaki Satoshi
Enrollment
38
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 1, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Iwasaki Satoshi

Eligibility Criteria

Inclusion Criteria

  • General criteria
  • (1\) Patient agreed to participate in the study and signed to the informed consent document.
  • (if patient is a monor, patiens or legal guardians sign to the informed consent document.)
  • (2\) Age of 6 years or older when agreed.
  • Audiological criteria
  • (1\) The patient withbpost\-lingual onset unilateral severe to profound sensorineural hearing loss.
  • (2\) The pure tone average (500Hz, 1000Hz, 2000Hz, and 4000Hz) of affected side was 70dBHL or more, or 30% or less speech perception score in affected ear with hearing aid.
  • (3\) The onset of hearing loss was 6 months or more and expect the insufficient improvement of hearing ability by conventional treatment.
  • (4\) The pure tone average (500Hz, 1000Hz, 2000Hz, and 4000Hz) of contralateral side was 40dBHL oe less.

Exclusion Criteria

  • The patients with below situations were exclude from this study.
  • (1\) Hearing recovery was observed in past 6 month greater than 15dB.
  • (2\) Cochear ossification in patients with hearing loss (meningitis, otosclerosis).
  • (3\) Severe malformation and cochlear obstraction.
  • (4\) Severe outer ear malformation and does not wear audioprosessor.
  • (5\) High risk for general anesthesia.
  • (6\) Active middle eat infection.
  • (7\) Clearly evidenced retro\-labryinthine hearing loss adult.
  • (8\) Severe mental retardation adult.

Outcomes

Primary Outcomes

Not specified

Similar Trials